In the News

Veronica Gutierrez Martinez and Michael Tokar discuss the challenges of setting up MAPs and the various considerations that must be tackled for a successful programme.

Jack Martin and Deirdre Albertson provide insights on ensuring patient safety and cardiovascular clinical trial integrity during a global pandemic.

An article in Pharmexec examining mistakes made in relation to Health Technology Assessments (HTA) and strategies to help reduce risks of future mistakes.

How COVID-19 has changed pharmacovigilance. Explores how drug safety can be ensured while numerous vaccines and treatments come to market to deal with COVID-19.

An article reporting on the growth of ICON as it acquires PRA Health Sciences.

ICON is set to acquire rival contract research organisation (CRO) PRA Health Sciences in a deal worth approximately $12bn.

A radio intervew with ICON CEO Steve Cutler about the ICON-PRA Health Sciences deal, which is the largest healthcare transaction this year at $12 billion.

ICON has agreed to acquire PRA Health Sciences for approximately $12 billion in cash and stock, in a deal that continues the consolidation of contract research organisations into a handful of corporate giants.

The deal consolidates two significant players in the contract research organisation arena, in a deal worth approximately $12b USD.

An interview with ICON CFO Brendan Brennan on ICON’s $12B acquisition of PRA Health Sciences.